CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
- Strong positive sales trajectory for rhCollagen based products
- Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human Collagen
- Readying sites to begin large-animal study planned in the second half of 2023 to advance 3D bioprinted regenerative breast implant program
- Conference call to be held on May 24, 2023 at 10:00 am
U.S. ET; Dial-in information herein
REHOVOT,
"Recently, we announced a collaborative agreement with Stratasys, a world-leader in 3D printing as well as completed the first large-animal study for our 3D bioprinted regenerative breast implants," said CollPlant's Chief Executive Officer, Yehiel Tal. "The agreement with Stratasys allows us to utilize their proprietary 3D printer technology and combine this with our state-of-the-art rhCollagen-based bioinks to enable high-resolution, scalable, and reproduceable bioprinting of scaffolds that accurately mimic the physical properties of human tissues and organs. The combined proprietary technologies will allow for 3D tissue and organ fabrication that also possess differentiated, regenerative properties."
Mr. Tal continued, "In addition, in the first quarter of 2023, we successfully completed a large-animal study for our regenerative breast implants as a precursor to a second large-animal study that we plan to initiate in the second half of this year. Trial sites are currently being secured and we look forward to providing an update as soon as this study begins. Our production of regenerative, non-animal derived, recombinant human collagen is the hallmark of our technology platform and continues to show promise for broad application spectrum."
Recent Corporate Highlights
Program development
- In January 2023, CollPlant announced that it successfully completed a large-animal study for its 3D bioprinted regenerative breast implants. The preclinical study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants, with no adverse events reported. Based on these positive results, the Company is planning to initiate a follow-up, second, large-animal study in the second half of 2023 to support subsequent human studies and future product commercialization.
- In the
U.S. alone, hundreds of thousands of people per year experience adverse events that range from autoimmune symptoms to the very serious breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's breast implants that are comprised of the Company's proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue without eliciting immune response, and thus may provide a revolutionary alternative for aesthetic and reconstructive procedures, including postmastectomy for cancer patients.
Collaboration updates
- CollPlant has the potential to receive additional milestone payments as well as future royalties in accordance with its long-term collaboration with AbbVie for its first-generation dermal filler. CollPlant has stated that it expects that the first of these milestones could be achieved in 2023.
- In April 2023, CollPlant announced a joint development and commercialization agreement with Stratasys (Nasdaq: SYSS) to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys' P3™ 3D technology-based bioprinter and CollPlant's rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale solution for CollPlant's regenerative breast implants program. Under the agreement, both companies have also agreed to cross-promote each other's bioprinting products.
- CollPlant is also developing a photocurable regenerative soft tissue filler developed for use in aesthetic medicine. It is based on a holistic platform technology which combines the properties of rhCollagen with hyaluronic acid creating a contouring effect.
- Twelve-month study results from a long-term, preclinical study to advance the development of CollPlant's photocurable dermal and soft-tissue filler demonstrated superior tissue regeneration, lifting capacity and volume retention when compared to a commercial standard. CollPlant has granted its global pharmaceutical partner, AbbVie, the right of first negotiation to obtain a worldwide exclusive license to this product.
- CollPlant remains engaged in partnering discussions with several industry leaders and academic institutions interested in the Company's rhCollagen technology and expertise in 3D bioprinting to develop therapeutics and medical applications.
Commercial portfolio of bioink solutions
- In January 2023, CollPlant expanded its commercial portfolio of rhCollagen-based bioinks adding Collink.3D-50L, to Collink.3D-50 and Collink.3D-90. CollPlant's bioink platform is intended to enable its customers to streamline the process of new product development while also accelerating timelines and reducing overall costs. CollPlant's new bioink, Collink.3D-50L is the first bioink available in powder form which provides enhanced operational flexibility for the end-user because of its mechanical properties to address additional printing requirements of soft and hard tissues.
- Fundamental optionality is expanded with CollPlant's new bioinks since they will enable both specificity and flexibility for the end user for use in a wide range of 3D bioprinting applications, including drug discovery, drug screening and tissue testing, as well as the development of transplantable tissues and organs. In addition to partnering with other research institutions and companies to supply its rhCollagen bioink products, CollPlant plans to apply the many beneficial characteristics of its portfolio of bioinks to develop small tissues and organs, and, prospectively partner with large pharmaceutical companies for larger organs.
- For its gut-on-a-chip program, CollPlant is developing a diagnostic tool for use in personalized medicine. In November of last year, CollPlant signed a collaboration agreement with
Tel-Aviv University and Sheba Medical Center to co-develop a bioprinted human intestine model for drug discovery and personalized treatment of ulcerative colitis. The 3D bioprinted model is designed to emulate the human intestine tissue in order to allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
First Quarter Financial Results
GAAP revenues for the first quarter ended March 31, 2023, were
GAAP cost of revenue for the first quarter ended March 31, 2023, was
GAAP gross profit for the first quarter ended March 31, 2023 was
GAAP operating expenses for the first quarter ended March 31, 2023, were
GAAP financial expenses, net for the first quarter of 2023 totaled
GAAP net loss for the first quarter ended March 31, 2023 was
Cash, cash equivalents and short-term deposits as of March 31, 2023, were
Cash used in operating activities during the first quarter of 2023, was
Cash used in investing activities during the first quarter of 2023, was
Cash provided by financing activities during the first quarter of 2023 was
Conference call information
CollPlant will hold a conference call to discuss its first quarter 2023 financial results along with corporate updates on May 24, 2023 at 10 am ET. To participate in the conference call, please use the dial-in information below:
To participate in the conference call, please use the dial-in information below:
U.S. investors: 1-877-407-9716
Investors outside of the
Conference ID: 13737936
Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the scheduled call start time:
ViaVid Call Me Join your Chorus Call teleconference in High Definition Audio! Use your browser or download the HD App!
Submit questions to management in advance of the call
To ask management a question ahead of the call, please email John Mullaly at LifeSci Advisors LLC up until 24 hours before the event at jmullaly@lifesciadvisors.com.
COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED BALANCE SHEETS ( | ||||||||
March 31, | December 31, | |||||||
Unaudited | Audited | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 26,528 | $ | 29,653 | ||||
Restricted deposit | 22 | 23 | ||||||
Trade receivables | 323 | 9 | ||||||
Other accounts receivable and prepaid expenses | 408 | 543 | ||||||
Inventories | 1,782 | 1,430 | ||||||
Total current assets | 29,063 | 31,658 | ||||||
Non-current assets: | ||||||||
Restricted deposit | 240 | 188 | ||||||
Operating lease right-of-use assets | 3,380 | 2,711 | ||||||
Property and equipment, net | 2,845 | 2,966 | ||||||
Intangible assets, net | 231 | 245 | ||||||
Total non-current assets | 6,696 | 6,110 | ||||||
Total assets | $ | 35,759 | $ | 37,768 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED BALANCE SHEETS ( | ||||||||
March 31, | December 31, | |||||||
Unaudited | Audited | |||||||
Liabilities and shareholders' equity | ||||||||
Current liabilities: | ||||||||
Trade payables | $ | 885 | $ | 1,133 | ||||
Operating lease liabilities | 527 | 529 | ||||||
Accrued liabilities and other | 1,509 | 1,443 | ||||||
Total current liabilities | 2,921 | 3,105 | ||||||
Non-current liabilities: | ||||||||
Operating lease liabilities | 2,948 | 2,382 | ||||||
Total non-current liabilities | 2,948 | 2,382 | ||||||
Total liabilities | 5,869 | 5,487 | ||||||
Shareholders' Equity: | ||||||||
Ordinary shares, NIS 1.5 par value - authorized: 30,000,000 ordinary shares as of March 31, 2023 and December 31, 2022; issued and outstanding: 11,385,041 and 11,186,481 ordinary shares as of March 31, 2023 and December 31, 2022, respectively | 4,955 | 4,873 | ||||||
Additional paid in capital | 119,341 | 118,099 | ||||||
Currency translation differences | (969) | (969) | ||||||
Accumulated deficit | (93,437) | (89,722) | ||||||
Total shareholders' equity | 29,890 | 32,281 | ||||||
Total liabilities and shareholders' equity | $ | 35,759 | $ | 37,768 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS ( (Unaudited) | ||||||||
Three months ended | ||||||||
2023 | 2022 | |||||||
Revenues | $ | 433 | $ | 66 | ||||
Cost of revenues | 325 | 31 | ||||||
Gross Profit | 108 | 35 | ||||||
Operating expenses: | ||||||||
Research and development | 2,102 | 2,242 | ||||||
General, administrative and marketing | 1,525 | 1,561 | ||||||
Total operating loss | 3,519 | 3,768 | ||||||
Financial expenses, net | 196 | 92 | ||||||
Net loss | $ | 3,715 | $ | 3,860 | ||||
Basic net loss per ordinary share | $ | 0.33 | $ | 0.36 | ||||
Diluted net loss per ordinary share | $ | 0.33 | $ | 0.36 | ||||
Weighted average ordinary shares outstanding used in computation of basic net loss per share | 11,270,948 | 10,783,065 | ||||||
Weighted average ordinary shares outstanding used in computation of diluted net loss per share | 11,270,948 | 10,783,065 | ||||||
COLLPLANT BIOTECHNOLOGIES LTD. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ( (Unaudited) | ||||||||
Three months ended | ||||||||
2023 | 2022 | |||||||
Cash flows from operating activities: | ||||||||
Loss | $ | (3,715) | $ | (3,860) | ||||
Adjustments for: | ||||||||
Depreciation and amortization | 280 | 240 | ||||||
Gains from Short term cash deposits | - | (36) | ||||||
Share-based compensation to employees and consultants | 514 | 461 | ||||||
Exchange differences on cash and cash equivalents | 282 | 228 | ||||||
Changes in operating asset and liability items: | ||||||||
Decrease (increase) in trade receivables | (314) | 270 | ||||||
Increase in inventories | (345) | (186) | ||||||
Decrease in other receivables | 135 | 161 | ||||||
Decrease in operating right of use assets | 119 | 110 | ||||||
Decrease in trade payables | (248) | (31) | ||||||
Decrease in lease liabilities | (224) | (204) | ||||||
Increase (decrease) in accrued liabilities and other payables | 66 | (333) | ||||||
Decrease in deferred revenues | - | (32) | ||||||
Net cash used in operating activities | (3,450) | (3,212) | ||||||
Cash flows from investing activities: | ||||||||
Capitalization of intangible assets | - | (6) | ||||||
Purchase of property and equipment | (145) | (296) | ||||||
Repayment of short term deposits | - | 30,187 | ||||||
Net cash provided by (used in) investing activities | (145) | 29,885 | ||||||
Cash flows from financing activities: | ||||||||
Exercise of options and warrants into shares | 803 | 1,474 | ||||||
Net cash provided by financing activities | 803 | 1,474 | ||||||
Increase (decrease) in cash and cash equivalents and restricted deposits | (2,792) | 28,147 | ||||||
Cash and cash equivalents and restricted deposits at the beginning of the period | 29,864 | 13,374 | ||||||
Exchange differences on cash and cash equivalents and restricted deposits | (282) | (228) | ||||||
Cash and cash equivalents and restricted deposits at the end of the period | $ | 26,790 | $ | 41,293 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. APPENDICES TO CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ( (Unaudited) | ||||||||
Three months ended | ||||||||
2023 | 2022 | |||||||
Appendix to the statement of cash flows | ||||||||
A. Supplementary information on investing and financing activities not involving cash flows: | ||||||||
Obtaining right of use assets in exchange for a lease liability | 788 | 24 | ||||||
Capitalization of Share-based compensation to inventory | 7 | - | ||||||
B. Reconciliation of Cash, cash equivalents and restricted cash at the end of the period | ||||||||
Cash and cash equivalents | 26,528 | 41,072 | ||||||
Restricted deposits (including long term) | 262 | 221 | ||||||
Total cash and cash equivalents and restricted deposits | $ | 26,790 | $ | 41,293 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. Reconciliation of GAAP to Non-GAAP Financial Measures ( (Unaudited) | ||||||||
Three months ended | ||||||||
2023 | 2022 | |||||||
GAAP gross profit | $ | 108 | $ | 35 | ||||
GAAP operating costs and expenses: | 3,627 | 3,803 | ||||||
Change of operating lease accounts | 21 | 94 | ||||||
Share-based compensation to employees, directors and consultants | (514) | (461) | ||||||
Non-GAAP operating costs and expenses: | 3,134 | 3,436 | ||||||
GAAP operating loss | 3,519 | 3,768 | ||||||
Non-GAAP operating loss | 3,026 | 3,401 | ||||||
GAAP net loss | 3,715 | 3,860 | ||||||
Change of operating lease accounts | 105 | 94 | ||||||
Share-based compensation to employees, directors and consultants | (514) | (461) | ||||||
Non-GAAP net loss | $ | 3,306 | $ | 3,493 | ||||
GAAP Basic net loss per ordinary share | $ | 0.33 | $ | 0.36 | ||||
GAAP diluted net loss per ordinary share | 0.33 | 0.36 | ||||||
Non-GAAP Basic net loss per ordinary share | $ | 0.29 | $ | 0.32 | ||||
Non-GAAP diluted net loss per ordinary share | 0.29 | 0.32 | ||||||
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Use of Non-US GAAP ("non-GAAP")
Financial results for 2023 and 2022 are presented on both a GAAP and a non-GAAP basis. GAAP results were prepared in accordance with
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors. The non-GAAP financial measures used by the Company in this press release may be different from the measures used by other companies.
For more information on the non-GAAP financial measures, please see the "Reconciliation of GAAP to Non-GAAP Financial Measures" later in this release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.
The Company's consolidated financial results for the first quarter ended March 31, 2023, are presented in accordance with generally accepted accounting principles in the
A copy of the Company's annual report on Form 20-F for the year ended December 31, 2022 has been filed with the
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
John Mullaly
jmullaly@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-announces-first-quarter-financial-results-for-2023-and-provides-corporate-update-301833271.html
SOURCE CollPlant
